Houston (1)

CCND1 Positive (1)

CCND2 Positive (1)

CCND3 Positive (1)

CD20 Positive (1)

Mantle Cell Lymphoma (1)

Recurrent Mantle Cell Lymphoma (1)

Refractory Mantle Cell Lymphoma (1)

Active, not recruiting (1)

phase 2 (1)

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

ibrutinib (1)

laboratory biomarker analysis (1)

rituximab (1)

biological (1)

drug (1)

other (1)

Other (1)

Interventional (1)

ccnd2 positive

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Jan 11, 2022